Total and Phospho-Tau Levels in an Animal Model of Alzheimer’s Disease: A Cross-Platform Comparison of Biomarker Measurements

Neurodegenerative disorders are multifactorial with unpredictable onset and rate of progression. At Sygnature Discovery, we investigated neurodegenerative biomarkers levels that allow the detection and tracking of disease progression and therapeutic efficacy of significant medical value.

Using Jess-based western blotting platform and ELISA assay, we investigated changes in total-Tau and phospho-Tau (pTau) levels in different brain regions of a wild-type (WT) and P301S transgenic mouse model of Alzheimer`s Disease. Our data highlights the importance of validating different sample normalization techniques and corroborates that pTau can be differentially expressed in the brain, which could implicate distinct pathophysiological mechanisms to the progression of Alzheimer`s disease.